A new immunotherapy drug could spare some bowel patients life-changing surgery, results of a trial suggest.
When given with radiotherapy and chemotherapy, durvalumab can destroy cancers in the lower part of the bowel – removing the need for an operation.
Currently, around half of patients with this type of bowel cancer – rectal cancer – will have surgery resulting in a stoma, a pouch which collects waste products outside of the body.
Load More
Yorumlar
Kalan Karakter: